Literature DB >> 16802209

Screening of compactin-resistant microorganisms capable of converting compactin to pravastatin.

Chao-Hsien Chen1, Hui-Yu Hu, Yen-Ching Cho, Wen-Hwei Hsu.   

Abstract

A simple method of using compactin for effective screening of microbial strains with high hydroxylation activity at the 6beta position of compactin was developed. Agar plates containing different carbon sources and 500 microg compactin mL(-1) were used to screen the microorganisms that can convert compactin to pravastatin. About 100 compactin-resistant strains were isolated from the Basal agar containing 7% (w/v) mannitol as a carbon source, in which two bacteria, Pseudomocardia autotrophica BCRC 12444 and Streptomyces griseolus BCRC 13677, capable of converting compactin to pravastatin with the yield of 20 and 32% (w/w), respectively, were found. High-performance liquid chromatography using C-18 column and two sequential mobile phases, 30% and 50% (v/v) acetonitrile, was also established to simultaneously determine the concentration of compactin and pravastatin in the culture broth. As such, about 2% of target microorganisms could be obtained from the screening program.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16802209     DOI: 10.1007/s00284-005-0276-7

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  13 in total

1.  Bioconversion of compactin into pravastatin by Streptomyces sp.

Authors:  Joo-Woong Park; Joo-Kyung Lee; Tae-Jong Kwon; Dong-Hee Yi; Young-Jun Kim; Seong-Hoon Moon; Hyun-Hyo Suh; Sang-Mo Kang; Yong-Il Park
Journal:  Biotechnol Lett       Date:  2003-11       Impact factor: 2.461

2.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.

Authors:  A Endo; M Kuroda; Y Tsujita
Journal:  J Antibiot (Tokyo)       Date:  1976-12       Impact factor: 2.649

3.  Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection.

Authors:  Steffen Bauer; Jessica Mwinyi; Angela Stoeckle; Thomas Gerloff; Ivar Roots
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-04-25       Impact factor: 3.205

4.  16S ribosomal DNA amplification for phylogenetic study.

Authors:  W G Weisburg; S M Barns; D A Pelletier; D J Lane
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

5.  6 alpha-Hydroxy-iso-ML-236B (6 alpha-hydroxy-iso-compactin) and ML-236A, microbial transformation products of ML-236B.

Authors:  N Serizawa; K Nakagawa; Y Tsujita; A Terahara; H Kuwano; M Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1983-07       Impact factor: 2.649

6.  Microbial hydroxylation of ML-236B (compactin). Studies on microorganisms capable of 3 beta-hydroxylation of ML-236B.

Authors:  N Serizawa; S Serizawa; K Nakagawa; K Furuya; T Okazaki; A Terahara
Journal:  J Antibiot (Tokyo)       Date:  1983-07       Impact factor: 2.649

7.  3 alpha-Hydroxy-ML-236B (3 alpha-hydroxycompactin), microbial transformation product of ML-236B (compactin).

Authors:  N Serizawa; K Nakagawa; Y Tsujita; A Terahara; H Kuwano
Journal:  J Antibiot (Tokyo)       Date:  1983-05       Impact factor: 2.649

8.  Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.

Authors:  T Matsuoka; S Miyakoshi; K Tanzawa; K Nakahara; M Hosobuchi; N Serizawa
Journal:  Eur J Biochem       Date:  1989-10-01

9.  A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Authors:  N Serizawa; T Matsuoka
Journal:  Biochim Biophys Acta       Date:  1991-06-19

10.  Application of computer to monitoring and control of fermentation process: Microbial conversion of ML-236B Na to pravastatin.

Authors:  M Hosobuchi; K Kurosawa; H Yoshikawa
Journal:  Biotechnol Bioeng       Date:  1993-09-20       Impact factor: 4.530

View more
  3 in total

Review 1.  Engineered biosynthesis of natural products in heterologous hosts.

Authors:  Yunzi Luo; Bing-Zhi Li; Duo Liu; Lu Zhang; Yan Chen; Bin Jia; Bo-Xuan Zeng; Huimin Zhao; Ying-Jin Yuan
Journal:  Chem Soc Rev       Date:  2015-05-11       Impact factor: 54.564

2.  Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.

Authors:  Kirsty J McLean; Marcus Hans; Ben Meijrink; Wibo B van Scheppingen; Aad Vollebregt; Kang Lan Tee; Jan-Metske van der Laan; David Leys; Andrew W Munro; Marco A van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

3.  Strain Improvement of Streptomyces xanthochromogenes RIA 1098 for Enhanced Pravastatin Production at High Compactin Concentrations.

Authors:  Vakhtang V Dzhavakhiya; Tatiana M Voinova; Elena V Glagoleva; Dmitry V Petukhov; Alexander I Ovchinnikov; Maksim I Kartashov; Boris B Kuznetsov; Konstantin G Skryabin
Journal:  Indian J Microbiol       Date:  2015-05-21       Impact factor: 2.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.